VA
FDMT icon

Vident Advisory’s 4D Molecular Therapeutics FDMT Stock Holding History

Vident Advisory’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-8,600
Closed -$274K – 1442
2024
Q1 		$274K Buy
+8,600
New +$219K 0.01% 1083
2023
Q4 		– Sell
-10,574
Closed -$135K – 1335
2023
Q3 		$135K Buy
+10,574
New +$177K ﹤0.01% 1176

Other funds holding FDMT

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vident Advisory's FDMT Position: Q2 2024 in Review

Vident Advisory sold out of 4D Molecular Therapeutics (FDMT) in Q2 2024, closing a stake of 8,600 shares — an estimated $274K sold.

Vident Advisory first reported a position in FDMT in Q3 2023 and held it in 2 quarters. The position peaked at $274K in Q1 2024. 143 funds tracked by Wall St. Rank hold FDMT as of Q2 2024.

  • Vident Advisory reported no remaining 4D Molecular Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Vident Advisory sold 8,600 4D Molecular Therapeutics shares in Q2 2024, an estimated $274K.
  • Vident Advisory first reported a position in 4D Molecular Therapeutics in Q3 2023 and held it in 2 quarters.
  • Vident Advisory's 4D Molecular Therapeutics position peaked at $274K in Q1 2024.
  • 143 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2024.

Based on Vident Advisory's 13F filing for Q2 2024, filed 14 Aug 2024.